Daxor’s BVA-100 Device Reveals Unexpected Blood Loss of 38 Percent in Cardiac Surgical Patients

Daxor Corporation, an investment company with medical instrumentation and biotechnology operations, announces the publication of new research utilizing the BVA-100 blood volume analyzer that highlights significant, often unrecognized blood loss in cardiac surgery. The paper entitled “Measurement of Blood Loss in Cardiac Surgery: Still Too Much” appears in The Annals of Thoracic Surgery.
 
Study author Mark Nelson, M.D., of Virginia Commonwealth University, stated that the surprising results of his study showed the inadequacy of current methods of evaluating blood loss, including the widespread use of hematocrit and hemoglobin: “Contrary to the long-held belief that red blood cells are largely conserved during cardiac surgery they are in fact reduced by 38 percent. This data beckons the question of transfusion, should peripheral hematocrit continue to be utilized as a determinant,” he said.
 
Michael Feldschuh CEO of Daxor stated, “This study highlights the BVA-100’s ability to illuminate intravascular fluid derangements that are missed by standard diagnostic tests. With over 500,000 coronary bypass surgeries, 3,200 transplants, and hundreds of thousands of other cardiac and non-cardiac surgeries performed annually in the United States, the need for optimal care and accurate measurement of surgical blood loss is acute. We see this as a very large and significant additional market for our product and look forward to subsequent research studies planned in this area.”
 
Surgical and non-surgical anemia caused by blood loss is a common ailment that poses significant risk to patients. Standard tests for determining blood loss or anemia lack the specificity and sensitivity of the BVA-100 test, which precisely quantifies whole blood and red blood cell volume with 98 percent accuracy.

Daxor is a biotechnology company that provides original medical equipment for medical personnel. The company manufactures the BVA-100 Blood Volume Analyzer, the first machine approved by the U.S. Food and Drug Administration that provides rapid direct measurement of a patient’s blood volume. The company claims the BVA-100 Blood Volume Analyzer has the potential to transform therapy in a broad range of surgical and medical conditions.